Semaphorin 4D

Semaphorin 4D

Semaphorin 4D 詳細

Molecule Name
Semaphorin 4D
分子の別称
SEMA4D,C9orf164,CD100,FLJ33485,FLJ34282,FLJ39737,FLJ46484,M-sema-G,MGC169138,MGC169141,SEMAJ,coll-4,Semaphorin-4D
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
SEMAJ,SEMA4D,Semaphorin 4D,Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) And Short Cytoplasmic Domain, (Semaphorin) 4D,C9orf164,CD100,BB18,GR3,A8,Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) And Short Cytoplasmic Domain, 4D,Chromosome 9 Open Reading Frame 164,CD100 Antigen,M-Sema-G,M-Sema G,Coll-4,COLL4,FLJ39737,Semaphorin-4D
バックグランド
Cluster of Differentiation 100 (CD100) is also known as Semaphorin-4D (SEMA4D), is a single-pass type I membrane protein which belongs to the semaphorin family, and is a human 150-kDa homodimer expressed at the surface of most hemopoietic cells. Semaphorin genes encode soluble and membrane-bound proteins, most of which have been shown to act as chemorepellents on growth cone guidance. CD100 is discrete, as it is a transmembrane leukocyte surface molecule that can also exist in a soluble form. Semaphorin 4D (Sema 4D) is an axon guidance molecule which is secreted by oligodendrocytes and induces growth cone collapse in the central nervous system. By binding plexin B1 receptor it functions as an R-Ras GTPase-activating protein (GAP) and repels axon growth cones in both the mature central nervous system. In the immune system, CD100 binds CD72 to activate B cells and dendritic cells, though much about this interaction is still under investigation. It is involved in oligodendrogenesis during development and during recovery from ischemic injury.

Semaphorin 4D 製品リスト

Species
  • Human(1)
Tag
  • Fc Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
Semaphorin 4D
Human Semaphorin 4D / SEMA4D / CD100 Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISA

$295.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
PepinemabVX-15; VX-15/2503; moAb VX-15/2503Phase 2 ClinicalVaccinex Inc
Alzheimer Disease; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Huntington Disease; Melanoma; Multiple Sclerosis; Osteosarcoma; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
Customer Reviews